Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 13, 2010
Grant Date -
Oct 11, 2007
app pub date -
Mar 23, 2007
filing date -
Jun 20, 2005
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antiviral and/or antitumor agents. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of combination therapy are also described.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully